Conference Coverage

Denosumab's benefits persist through 8 years

Publish date: July 2, 2014

 

AT ICE/ENDO 2014

bjancin@frontlinemedcom.com

Pages

Recommended Reading

No survival benefit to bisphosphonate in chemoresistant breast cancer
MDedge Family Medicine
Romosozumab boosts bone density while cutting resorption
MDedge Family Medicine
New stroke guidelines focus on women’s risks
MDedge Family Medicine
VIDEO: Moderate exercise reduced women’s stroke risk
MDedge Family Medicine
Moderate exercise reduces female stroke risk
MDedge Family Medicine
It’s time to put to rest the calcium supplement controversy
MDedge Family Medicine
Menopause doesn’t drive severe asthma
MDedge Family Medicine
Topical lidocaine reduces menopausal dyspareunia
MDedge Family Medicine
Women’s Health Initiative study netted $37 billion in savings
MDedge Family Medicine
Yearly monitoring does not predict fractures after bisphosphonate cessation
MDedge Family Medicine